Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Resch, B; Müller, W.
Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)
Klin Padiatr. 1999; 211(6):450-455
Doi: 10.1055/s-2008-1043832
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Resch Bernhard
- Co-Autor*innen der Med Uni Graz
- Müller Wilhelm
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Respiratory syncytial virus (RSV) causes seasonal epidemics between December and March (April) and remains the main agent that causes severe lower respiratory tract infections in young infants. Children with bronchopulmonary dysplasia up to 24 months of age and preterm infants with a gestational age of 32 weeks and below, who are less than six months of age, are at highest risk for severe RSV infection. RSV-IGIV has been demonstrated to reduce significantly RSV associated hospitalizations, RSV associated hospital days and the incidence of severe RSV lower respiratory tract infections. Monthly infusions during RSV season were safe and well tolerated. Adverse events related to the hyperimmune globulin infusion were generally mild (< 3%) including fluid overload, decreased oxygen saturation and fever. Palivizumab, an intramuscularly administered humanized monoclonal antibody (RSV-glycoprotein-F antibody), will be preferable for the future because of ease of administration and comparable reduction in the risk of hospitalization. RSV-IGIV and palivizumab are both cost expansive and prophylaxis should be limited to high-risk infants.
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Monoclonal - economics
- Austria - epidemiology
- Bronchopulmonary Dysplasia - complications
- Cost-Benefit Analysis - complications
- Drug Approval - complications
- Humans - complications
- Immunoglobulins, Intravenous - economics
- Infant - economics
- Infant, Newborn - economics
- Infant, Premature, Diseases - epidemiology
- Randomized Controlled Trials - epidemiology
- Respiratory Syncytial Virus Infections - complications
- Respiratory Syncytial Virus, Human - drug effects
- United States - drug effects
- Find related publications in this database (Keywords)
- Respiratory Syncytial Virus
- Bronchopulmonary Dysplasia
- Prematurity
- Respiratory Syncytial Virus Hyperimmune Globulin
- Palivizumab